{"id":"W2908553092","doi":"10.1016/s1474-4422(18)30405-8","title":"Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Neurology","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval","funders":"National Institute of Neurological Disorders and Stroke; School of Public Health, University of California Berkeley; St. Jude Medical; National Institutes of Health; Sunovion; H. Lundbeck A/S; Parkinson Study Group; Kyowa Kirin Pharmaceutical Development; AstraZeneca; International Parkinson and Movement Disorder Society; Acorda Therapeutics; Abbott Laboratories; Śląski Uniwersytet Medyczny; AbbVie; CHDI Foundation; Roche; Novartis; Adamas Pharmaceuticals; ACADIA Pharmaceuticals; Merck; US WorldMeds; National Parkinson Foundation; Pfizer; Michael J. Fox Foundation for Parkinson's Research; American Parkinson Disease Association; Teva Pharmaceutical Industries; Kyowa Hakko Kirin","keywords":"Levodopa; Placebo; Medicine; Parkinson's disease; Clinical endpoint; Inhaler; Inhalation; Physical therapy; Clinical trial; Internal medicine; Anesthesia; Disease; Asthma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002875657,0.0002365576,0.0008610797,0.0001619097,0.00007420725,0.00001295981,0.00007909015,0.00008474253,0.00008939555],"category_scores_gemma":[0.00008307776,0.0001456843,0.0001056272,0.0001294928,0.00005948399,0.00006750739,0.0000325883,0.0002261267,0.0000137369],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003184747,"about_ca_system_score_gemma":0.00006291408,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009136614,"about_ca_topic_score_gemma":0.000004148306,"domain_scores_codex":[0.9983574,0.0002897676,0.0003610439,0.0004101597,0.0002812689,0.0003003467],"domain_scores_gemma":[0.9988905,0.0002564853,0.0002575465,0.0004169667,0.00004842408,0.000130114],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9348096,0.001361235,0.06212348,0.00004566163,0.0001996697,0.00003310897,0.00006421867,0.000102696,0.0002360331,0.00005261306,0.000005061409,0.0009666231],"study_design_scores_gemma":[0.6301931,0.004060632,0.3645729,0.00002937217,0.0002744307,0.000002680544,0.000002765086,0.0003107037,0.00003636104,0.00001375247,0.0004290708,0.00007428473],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992934,0.0001538074,0.000008249732,0.0006399911,0.0002435919,0.005769015,0.00003590634,0.00003501067,0.0001804565],"genre_scores_gemma":[0.9990078,0.00007160836,0.000006232964,0.0003197025,0.0001761399,0.0002246594,0.00007401052,0.00002854502,0.00009134028],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3046165,"threshold_uncertainty_score":0.5940832,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01526237623651743,"score_gpt":0.2623306480630693,"score_spread":0.2470682718265519,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}